Suppr超能文献

同位素标记与不同组织学分级肝病患者肝三酰甘油的生化评估。

Isotope Labeling and Biochemical Assessment of Liver-Triacylglycerol in Patients with Different Levels of Histologically-Graded Liver Disease.

机构信息

Department of Nutrition and Exercise Physiology, University of Missouri, Columbia, MO, United States.

Department of Nutrition and Exercise Physiology, University of Missouri, Columbia, MO, United States; Research Services-Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, United States.

出版信息

J Nutr. 2023 Dec;153(12):3418-3429. doi: 10.1016/j.tjnut.2023.09.018. Epub 2023 Sep 27.

Abstract

BACKGROUND

Nonalcoholic fatty liver disease (NAFLD) prevalence is rapidly growing, and fatty liver has been found in a quarter of the US population. Increased liver lipids, particularly those derived from the pathway of de novo lipogenesis (DNL), have been identified as a hallmark feature in individuals with high liver fat. This has led to much activity in basic science and drug development in this area. No studies to date have investigated the contribution of DNL across a spectrum of disease, although it is clear that inhibition of DNL has been shown to reduce liver fat.

OBJECTIVES

The purpose of this study was to determine whether liver lipid synthesis increases across the continuum of liver injury.

METHODS

Individuals (n = 49) consumed deuterated water for 10 d before their scheduled bariatric surgeries to label DNL; blood and liver tissue samples were obtained on the day of the surgery. Liver lipid concentrations were quantitated, and levels of protein and gene expression assessed.

RESULTS

Increased liver DNL, measured isotopically, was significantly associated with liver fatty acid synthase protein content (R = 0.470, P = 0.003), total steatosis assessed by histology (R = 0.526, P = 0.0008), and the fraction of DNL fatty acids in plasma very low-density lipoprotein-triacylglycerol (R = 0.747, P < 0.001). Regression analysis revealed a parabolic relationship between fractional liver DNL (percent) and NAFLD activity score (R = 0.538, P = 0.0004).

CONCLUSION

These data demonstrate that higher DNL is associated with early to mid stages of liver disease, and this pathway may be an effective target for the treatment of NAFLD and nonalcoholic steatohepatitis. This study was registered at clinicaltrials.gov as NCT03683589.

摘要

背景

非酒精性脂肪性肝病 (NAFLD) 的患病率正在迅速上升,四分之一的美国人口患有脂肪肝。在肝脏脂肪含量高的人群中,已经发现肝内脂质增加,特别是来自从头合成 (DNL) 途径的脂质增加,这是一个标志性特征。这导致该领域的基础科学和药物开发活动非常活跃。迄今为止,尚无研究调查 DNL 在疾病谱中的贡献,尽管抑制 DNL 已被证明可减少肝脂肪。

目的

本研究旨在确定肝脂质合成是否在肝损伤连续体中增加。

方法

49 名个体在接受减肥手术前 10 天饮用氘水以标记 DNL;手术当天获得血液和肝组织样本。定量肝脂质浓度,并评估蛋白和基因表达水平。

结果

同位素测量的肝 DNL 增加与肝脂肪酸合酶蛋白含量显著相关(R = 0.470,P = 0.003),组织学评估的总脂肪变性(R = 0.526,P = 0.0008),以及 DNL 脂肪酸在血浆极低密度脂蛋白-三酰甘油中的分数(R = 0.747,P < 0.001)。回归分析显示,肝 DNL 分数(%)与 NAFLD 活动评分之间呈抛物线关系(R = 0.538,P = 0.0004)。

结论

这些数据表明,较高的 DNL 与肝病的早期至中期阶段相关,该途径可能是治疗 NAFLD 和非酒精性脂肪性肝炎的有效靶点。本研究在 clinicaltrials.gov 上注册为 NCT03683589。

相似文献

2
Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis.
Am J Clin Nutr. 2015 Jan;101(1):34-43. doi: 10.3945/ajcn.114.092262. Epub 2014 Nov 19.
3
Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease.
J Clin Invest. 2020 Mar 2;130(3):1453-1460. doi: 10.1172/JCI134165.
5
Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease.
Dig Dis Sci. 2016 May;61(5):1282-93. doi: 10.1007/s10620-016-4054-0. Epub 2016 Feb 8.
6
Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease.
Lipids Health Dis. 2016 Sep 17;15(1):159. doi: 10.1186/s12944-016-0321-5.
7
Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice.
Diabetologia. 2023 May;66(5):931-954. doi: 10.1007/s00125-023-05878-8. Epub 2023 Feb 10.
9
Pharmacologic inhibition of lipogenesis for the treatment of NAFLD.
J Hepatol. 2024 Feb;80(2):362-377. doi: 10.1016/j.jhep.2023.10.042. Epub 2023 Nov 15.
10
Investigating dual inhibition of ACC and CD36 for the treatment of nonalcoholic fatty liver disease in mice.
Am J Physiol Endocrinol Metab. 2023 Feb 1;324(2):E187-E198. doi: 10.1152/ajpendo.00161.2022. Epub 2023 Jan 11.

引用本文的文献

1
Weight loss in MASLD restores the balance of liver fatty acid sources.
J Clin Invest. 2025 May 1;135(9). doi: 10.1172/JCI174233.
3
Ketogenesis supports hepatic polyunsaturated fatty acid homeostasis via fatty acid elongation.
Sci Adv. 2025 Jan 31;11(5):eads0535. doi: 10.1126/sciadv.ads0535. Epub 2025 Jan 29.
4
Targeting acetyl-CoA carboxylases for the treatment of MASLD.
J Lipid Res. 2024 Dec;65(12):100676. doi: 10.1016/j.jlr.2024.100676. Epub 2024 Oct 25.
5
Histological improvements following energy restriction and exercise: The role of insulin resistance in resolution of MASH.
J Hepatol. 2024 Nov;81(5):781-793. doi: 10.1016/j.jhep.2024.06.017. Epub 2024 Jun 22.
6
What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
Lipids Health Dis. 2024 Feb 8;23(1):41. doi: 10.1186/s12944-024-02031-1.
7
Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD).
Metabolites. 2023 Dec 23;14(1):12. doi: 10.3390/metabo14010012.

本文引用的文献

2
Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score.
Hepatology. 2022 Oct;76(4):1150-1163. doi: 10.1002/hep.32475. Epub 2022 Apr 6.
3
Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD.
Hepatology. 2022 Nov;76(5):1452-1465. doi: 10.1002/hep.32324. Epub 2022 Apr 14.
4
Preparing for the NASH Epidemic: A Call to Action.
Gastroenterology. 2021 Sep;161(3):1030-1042.e8. doi: 10.1053/j.gastro.2021.04.074. Epub 2021 Jul 26.
5
Measurement of lipogenic flux by deuterium resolved mass spectrometry.
Nat Commun. 2021 Jun 18;12(1):3756. doi: 10.1038/s41467-021-23958-4.
6
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus.
Nat Rev Endocrinol. 2021 Aug;17(8):484-495. doi: 10.1038/s41574-021-00507-z. Epub 2021 Jun 15.
7
Metabolic drivers of non-alcoholic fatty liver disease.
Mol Metab. 2021 Aug;50:101143. doi: 10.1016/j.molmet.2020.101143. Epub 2020 Dec 17.
8
The metabolic basis of nonalcoholic steatohepatitis.
Endocrinol Diabetes Metab. 2020 Feb 24;3(4):e00112. doi: 10.1002/edm2.112. eCollection 2020 Oct.
10
Leptin decreases de novo lipogenesis in patients with lipodystrophy.
JCI Insight. 2020 Jul 23;5(14):137180. doi: 10.1172/jci.insight.137180.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验